Venture Capital Investments by Big Pharma
A Panel & Networking Event
Thursday September 27, 2007
• 3:00-3:30 PM Networking & Registration
• 3:30-5:00 PM Experts Panel
• 5:00-6:30 PM BBQ Networking Reception
2006 marked the highest level of investment since 2001. According to PricewaterhouseCoopers’ MoneyTree Report, the Life Sciences sector (Biotechnology and Medical Devices industries, together) set the pace for investing in 2006 with $7.2 billion in 731 deals. For the year, Life Sciences accounted for 28% of all venture capital invested and seed and early stage deals accounted for 34% of the total deals done in 2006. However, today, traditional VCs are not the only ones making these investments as many “Big Pharma” have created their own Venture Capital Investments Divisions to invest in bio companies. Join an expert panel of the most active Big Pharma VCs, a VC, and a company funded by a Big Pharma VC and discuss this new source of capital with a particular focus on the following 2 topics:
• Do’s & Don’ts: How to approach and attract them?
• Pros & Cons: How are they different from regular VCs?
The roundtable discussion format is interactive and informal and intended to be a conversation more than a presentation. So bring your questions with you!
Janis C. Naeve, Ph.D., Director, Amgen Ventures ~ Click Here for Bio
S. Edward Torres, Managing Director, Lilly Ventures ~ Click Here for Bio
Nancy E. Pfund, Managing Director, JP Morgan ~ Click Here for Bio
Peter Van Vlasselaer, Ph.D., President & CEO, Arresto BioSciences ~ Click Here for Bio
Gregory W. Heibel, Corporate Lawyer, Member of the Emerging Companies Group, Orrick, Herrington & Sutcliffe LLP ~ Click for Bio
Moderator & Panelists' Bios
Gregory W. Heibel, Corporate Lawyer, Member of the Emerging Companies Group, Orrick, Herrington & Sutcliffe LLP
Gregory Heibel, a lawyer in the Silicon Valley office, is a member of the Emerging Companies practice group. Mr. Heibel focuses his practice on the representation of rapidly growing public and private technology companies, venture capital firms and other technology investors.
Mr. Heibel has also worked with Genevest, a venture capital firm in Geneva, Switzerland, where he participated in the first organizational meeting of the European Union World Wide Web Consortium. In addition, Mr. Heibel has worked with a number of venture capital backed technology companies in operational and advisory roles.
Before joining Orrick, Mr. Heibel was a lawyer with Venture Law Group.
Janis C. Naeve, Ph.D., Director, Amgen Ventures
Dr. Janis Naeve joined Amgen in 2005 and is currently Director for Amgen Ventures, the Company’s corporate venture capital fund. She manages deal flow evaluation and on-going oversight of investments in multiple portfolio companies.
Before joining Amgen, Dr. Naeve was Director of Corporate Development for X-Ceptor Therapeutics where she supported strategic planning including repositioning the company’s platform to a cardiovascular drug company. Her broad-based experience encompasses revenue generation in a profitable biotech, transitioning of a platform research company into preclinical/clinical development, and fundraising through venture capital or M&A.;
Naeve did her postdoctoral research work at Caltech after receiving her Ph.D. in Experimental Pathology from the University of Southern California. Naeve completed her undergraduate work in Medical Microbiology at California Polytechnic University.
S. Edward Torres, Managing Director, Lilly Ventures
Mr. Torres is a Managing Director of Lilly Ventures, the venture capital arm of Eli Lilly and Company, and has over 18 years of experience in the pharmaceutical and venture capital businesses. He led the investments in, and currently serves as a director of, Cylene Pharmaceuticals, Serenex, Fluidigm and Trinity Biosystems and previously served as a director of Conforma Therapeutics (acquired by Biogen Idec) and Cabrellis Pharmaceuticals (acquired by Pharmion). Prior to his role in Lilly Ventures, Mr. Torres had a diverse set of experiences throughout the domestic and international pharmaceutical businesses including operational finance, planning, M&A;, business development and global marketing roles. He received a bachelors of arts from Creighton University and a master of business administration from the University of Michigan Business School, where he was a Consortium Fellow.
Nancy E. Pfund, Managing Director, JPMorgan
Nancy E. Pfund is a Managing Director at JPMorgan. She co-heads JPMorgan's $75 million Bay Area Equity Fund, a double bottom-line private equity fund aimed at investing in emerging growth companies located in or near lower-income neighborhoods of the Bay Area. The Bay Area Equity Fund is bringing together traditional venture capitalists with community and government leaders to improve the overall sustainability of the Bay Area region by extending venture capital's reach. Ms. Pfund has sponsored numerous private equity investments while at JPMorgan, and currently sits on the boards of directors of a number of private companies, including SERA Learning Technologies, Elephant Pharmacy, and Efficas Corporation.
Ms. Pfund joined Hambrecht & Quist, now JPMorgan, in 1984 as a securities analyst and later joined its venture capital department as Principal in 1989. Ms. Pfund's scope has extended from technology to health care and consumer, and has included special concentrations in the environmental, education, and instrumentation-related sectors. In addition to her private equity responsibilities, Ms. Pfund also built and directed H&Q;'s external affairs and philanthropic programs from 1996 to 2001. In 1988, President Bush appointed Ms. Pfund as a charter member of the National Advisory Council for Environmental Policy and Technology. In 1999, Ms. Pfund was appointed by President Clinton to serve on the Congressional Web-Based Education Commission, which issued its report in the winter of 2000. Ms. Pfund is a member of the Board of Directors of the California Clean Energy Fund (CalCEF), and is a founding officer and director of ABC2, a foundation aimed at accelerating a cure for brain cancer.
She is also a member of the Advisory Board of the Yale University School of Management.
Prior to joining JPMorgan, Ms. Pfund worked at Intel Corporation, Stanford University, the State of California, and the Sierra Club. Ms. Pfund received her B.A. and M.A. in anthropology from Stanford University, and her MBA from the Yale School of Management.
Peter Van Vlasselaer, Ph.D., President & CEO, Arresto BioSciences
Dr. Van Vlasselaer is the President and CEO of Arresto BioSciences. Before that, he was CEO of Avidia, a venture-financed biotechnology company, until it was sold to Amgen in October 2006. Prior to joining Avidia, he was Senior Vice President of Technical Operations at InterMune, Inc. (NASDAQ: ITMN) and Vice President of Product Development at Dendreon, Inc. (NASDAQ: DNDN). Before that, Peter was Staff Scientist at the Center for Nuclear Research in Mol, Belgium, where he managed research in Hematology, Immunology and Bone Biology. He was at DNAX Research Institute (Schering-Plough), where he conducted research in human B cell biology.
Peter holds a B.S. in Zoology and a Ph.D. In Cellular Immunology from the University of Leuven, Belgium, and he was a Post-Doctoral Fellow at the Immunology and Rheumatology Division of the Stanford Medical School. He is inventor and author on multiple patents and publications in different fields, and was awarded the King Boudewijn Award for young entrepreneurs in Belgium.